JP2003517041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003517041A5 JP2003517041A5 JP2001545542A JP2001545542A JP2003517041A5 JP 2003517041 A5 JP2003517041 A5 JP 2003517041A5 JP 2001545542 A JP2001545542 A JP 2001545542A JP 2001545542 A JP2001545542 A JP 2001545542A JP 2003517041 A5 JP2003517041 A5 JP 2003517041A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- seq
- phosphodiester nucleotide
- synthetic phosphodiester
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001850 Nucleic acid sequence Polymers 0.000 description 12
- 150000004713 phosphodiesters Chemical class 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 3’−OH,5'−OH合成ホスホジエステルヌクレオチド配列、化学療法剤、及び薬学的に許容可能なキャリアを含む組成物であって、前記合成ホスホジエステルヌクレオチド配列は配列番号8−10、25、26、41−43、45及び46からなる群から選択される、組成物。
【請求項2】 前記化学療法剤は、代謝拮抗物質、アルキル化剤又はホルモン拮抗物質である、請求項1に記載の組成物。
【請求項3】 前記合成ホスホジエステルヌクレオチド配列が配列番号8である、請求項1又は2に記載の組成物。
【請求項4】 前記合成ホスホジエステルヌクレオチド配列が配列番号9である、請求項1又は2に記載の組成物。
【請求項5】 前記合成ホスホジエステルヌクレオチド配列が配列番号10である、請求項1又は2に記載の組成物。
【請求項6】 前記合成ホスホジエステルヌクレオチド配列が配列番号25である、請求項1又は2に記載の組成物。
【請求項7】 前記合成ホスホジエステルヌクレオチド配列が配列番号26である、請求項1又は2に記載の組成物。
【請求項8】 前記合成ホスホジエステルヌクレオチド配列が配列番号41である、請求項1又は2に記載の組成物。
【請求項9】 前記合成ホスホジエステルヌクレオチド配列が配列番号42である、請求項1又は2に記載の組成物。
【請求項10】 前記合成ホスホジエステルヌクレオチド配列が配列番号43である、請求項1又は2に記載の組成物。
【請求項11】 前記合成ホスホジエステルヌクレオチド配列が配列番号45である、請求項1又は2に記載の組成物。
【請求項12】 前記合成ホスホジエステルヌクレオチド配列が配列番号46である、請求項1又は2に記載の組成物。
【請求項1】 3’−OH,5'−OH合成ホスホジエステルヌクレオチド配列、化学療法剤、及び薬学的に許容可能なキャリアを含む組成物であって、前記合成ホスホジエステルヌクレオチド配列は配列番号8−10、25、26、41−43、45及び46からなる群から選択される、組成物。
【請求項2】 前記化学療法剤は、代謝拮抗物質、アルキル化剤又はホルモン拮抗物質である、請求項1に記載の組成物。
【請求項3】 前記合成ホスホジエステルヌクレオチド配列が配列番号8である、請求項1又は2に記載の組成物。
【請求項4】 前記合成ホスホジエステルヌクレオチド配列が配列番号9である、請求項1又は2に記載の組成物。
【請求項5】 前記合成ホスホジエステルヌクレオチド配列が配列番号10である、請求項1又は2に記載の組成物。
【請求項6】 前記合成ホスホジエステルヌクレオチド配列が配列番号25である、請求項1又は2に記載の組成物。
【請求項7】 前記合成ホスホジエステルヌクレオチド配列が配列番号26である、請求項1又は2に記載の組成物。
【請求項8】 前記合成ホスホジエステルヌクレオチド配列が配列番号41である、請求項1又は2に記載の組成物。
【請求項9】 前記合成ホスホジエステルヌクレオチド配列が配列番号42である、請求項1又は2に記載の組成物。
【請求項10】 前記合成ホスホジエステルヌクレオチド配列が配列番号43である、請求項1又は2に記載の組成物。
【請求項11】 前記合成ホスホジエステルヌクレオチド配列が配列番号45である、請求項1又は2に記載の組成物。
【請求項12】 前記合成ホスホジエステルヌクレオチド配列が配列番号46である、請求項1又は2に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17032599P | 1999-12-13 | 1999-12-13 | |
US60/170,325 | 1999-12-13 | ||
US22892500P | 2000-08-29 | 2000-08-29 | |
US60/228,925 | 2000-08-29 | ||
PCT/CA2000/001467 WO2001044465A2 (en) | 1999-12-13 | 2000-12-12 | Therapeutically useful synthetic oligonucleotides |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2003517041A JP2003517041A (ja) | 2003-05-20 |
JP2003517041A5 true JP2003517041A5 (ja) | 2008-02-07 |
JP4772245B2 JP4772245B2 (ja) | 2011-09-14 |
Family
ID=26865979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001545542A Expired - Fee Related JP4772245B2 (ja) | 1999-12-13 | 2000-12-12 | 治療上有用な合成オリゴヌクレオチド |
Country Status (18)
Country | Link |
---|---|
US (2) | US7157436B2 (ja) |
EP (2) | EP1238070B1 (ja) |
JP (1) | JP4772245B2 (ja) |
KR (1) | KR100829646B1 (ja) |
CN (2) | CN100445380C (ja) |
AT (2) | ATE455851T1 (ja) |
AU (1) | AU785212B2 (ja) |
CA (1) | CA2393808A1 (ja) |
CZ (1) | CZ20022372A3 (ja) |
DE (2) | DE60036019T2 (ja) |
DK (2) | DK1238070T3 (ja) |
ES (2) | ES2288883T3 (ja) |
HU (1) | HUP0300627A3 (ja) |
IL (2) | IL150196A0 (ja) |
MX (1) | MXPA02005842A (ja) |
NO (1) | NO330508B1 (ja) |
PT (1) | PT1238070E (ja) |
WO (1) | WO2001044465A2 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030032610A1 (en) | 1996-06-03 | 2003-02-13 | Gilchrest Barbara A. | Method to inhibit cell growth using oligonucleotides |
PT1181304E (pt) | 1999-04-08 | 2008-01-23 | Antisoma Res Ltd | Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina |
US7960540B2 (en) | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
CN100445380C (zh) * | 1999-12-13 | 2008-12-24 | 拜昂尼科生命科学有限公司 | 治疗用合成寡核苷酸 |
AU6886301A (en) | 2000-08-29 | 2002-03-13 | Bioniche Life Sciences Inc | Modulation of fas and fasl expression |
ES2307568T3 (es) * | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
US7087586B2 (en) * | 2001-04-24 | 2006-08-08 | Bioniche Life Sciences, Inc. | Oligonucleotide compositions and their use to induce differentiation of cells |
EP1417307B1 (en) * | 2001-08-17 | 2009-04-15 | Bioniche Life Sciences Inc. | Oligonucleotide compositions and their use to induce apoptosis |
EP1432450B1 (en) * | 2001-10-03 | 2005-12-28 | Bioniche Life Sciences Inc. | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
AU2003219383B2 (en) * | 2002-04-22 | 2010-08-26 | Bioniche Life Sciences Inc. | Oligonucleotide compositions and their use for the modulation of immune responses |
WO2004087203A2 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
US7569554B2 (en) * | 2003-05-16 | 2009-08-04 | Idera Pharmaceuticals, Inc. | Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents |
CA2598992A1 (en) * | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
EP1863538A4 (en) * | 2005-03-09 | 2009-01-14 | Baylor College Medicine | DIRECT INVERSION OF CD4 + T CELL LYMPHOCYTE INHIBITOR FUNCTION VIA TOLL-TYPE 8 RECEIVER SIGNALING |
GB2443591B (en) * | 2005-09-07 | 2010-04-28 | Secr Defence | Adjuvanted vaccine |
ES2658626T3 (es) * | 2009-02-12 | 2018-03-12 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF |
GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
KR100998365B1 (ko) | 2009-06-29 | 2010-12-06 | 압타바이오 주식회사 | 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체 |
TW201102073A (en) * | 2009-07-15 | 2011-01-16 | Enzon Pharmaceuticals Inc | RNA antagonists targeting GLI2 for the treatment of leukemia |
WO2013129603A1 (ja) * | 2012-02-28 | 2013-09-06 | 国立大学法人東京農工大学 | Tdp-43細胞内存在量関連疾患の認定方法 |
EP4000597A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
CA3242118A1 (en) * | 2021-12-22 | 2023-06-29 | Alfica Sehgal | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3172815A (en) * | 1962-04-24 | 1965-03-09 | Warner Lambert Pharmaceutical | Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof |
US4152423A (en) * | 1971-11-19 | 1979-05-01 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunological agents |
FR2160326B1 (ja) * | 1971-11-19 | 1975-02-07 | Anvar | |
CH602920A5 (ja) * | 1973-02-23 | 1978-08-15 | Wellcome Found | |
US3976544A (en) * | 1973-06-19 | 1976-08-24 | The Agence Nationale De Valorisation De Le Recherche | Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction |
FR2374042A1 (fr) * | 1976-06-04 | 1978-07-13 | Merieux Inst | Nouveau medicament immunostimulant et son procede de preparation |
JPS54140710A (en) * | 1978-03-10 | 1979-11-01 | Mitsui Toatsu Chem Inc | Anti-tumor substance and its preparation |
DE3011461C2 (de) * | 1980-03-25 | 1986-10-30 | Dr. Madaus & Co, 5000 Köln | Verwendung von Propionibakterien |
US4520019A (en) * | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
US4579941A (en) * | 1982-08-13 | 1986-04-01 | Mitsuitoatsu Chemicals, Inc. | Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent |
US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
GB8404280D0 (en) * | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
US4744984A (en) * | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
DE3723075A1 (de) * | 1987-07-11 | 1989-01-19 | Boehringer Mannheim Gmbh | Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung |
US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
WO1992007095A1 (en) * | 1990-10-15 | 1992-04-30 | Stratagene | Arbitrarily primed polymerase chain reaction method for fingerprinting genomes |
AU1456092A (en) * | 1991-02-21 | 1992-09-15 | Gilead Sciences, Inc. | Aptamers specific for thrombin and methods of use |
CA2268476A1 (en) * | 1991-07-03 | 1998-04-30 | Hyal Pharmaceutical Corporation | Use of hyaluronan in gene therapy |
US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
ATE179333T1 (de) * | 1993-01-29 | 1999-05-15 | Vetrepharm Inc | Immunotherapeutische zubereitung |
US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
CN1154702A (zh) * | 1994-05-25 | 1997-07-16 | 海布里登公司 | 具有抗巨细胞病毒活性的寡核苷酸 |
US6211431B1 (en) * | 1994-08-30 | 2001-04-03 | Commonwealth Scientific And Industrial Research Organization | Plant transcription regulators from circovirus |
US5643890A (en) * | 1995-01-31 | 1997-07-01 | The Board Of Regents Of The University Of Nebraska | Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases |
IN181358B (ja) * | 1995-02-14 | 1998-05-30 | Bioniche Inc | |
ZA964446B (en) * | 1995-06-06 | 1996-12-06 | Hoffmann La Roche | Oligonucleotides specific for hepatitis c virus |
US5990299A (en) * | 1995-08-14 | 1999-11-23 | Icn Pharmaceuticals, Inc. | Control of CD44 gene expression for therapeutic use |
EA000841B1 (ru) * | 1995-11-21 | 2000-04-24 | Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ | Антисмысловые олигонуклеотиды к ил-8 и рецептору ил-8 и способ лечения злокачественных опухолей |
IT1277025B1 (it) * | 1995-12-04 | 1997-11-04 | Cooperativa Centro Ricerche Po | Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso |
US6015710A (en) * | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
ATE383172T1 (de) * | 1996-05-20 | 2008-01-15 | Us Gov Health & Human Serv | Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden |
KR100533576B1 (ko) * | 1997-08-05 | 2005-12-05 | 바이오니취 라이프 사이언시즈 인코포레이티드 | 세포증식 및 세포사멸 조절용 조성물 및 방법 |
US6255473B1 (en) * | 1997-08-29 | 2001-07-03 | Duke University | Presenilin-1 gene promoter |
DK1221955T3 (da) * | 1999-09-25 | 2006-01-30 | Univ Iowa Res Found | Immunstimulerende nukleinsyre |
CN100445380C (zh) * | 1999-12-13 | 2008-12-24 | 拜昂尼科生命科学有限公司 | 治疗用合成寡核苷酸 |
US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
AU784356B2 (en) * | 1999-12-28 | 2006-03-16 | Bioniche Urology Ip Inc. | Hyaluronic acid in the treatment of cancer |
EP1432450B1 (en) * | 2001-10-03 | 2005-12-28 | Bioniche Life Sciences Inc. | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
AU2003219383B2 (en) * | 2002-04-22 | 2010-08-26 | Bioniche Life Sciences Inc. | Oligonucleotide compositions and their use for the modulation of immune responses |
-
2000
- 2000-12-12 CN CNB008188580A patent/CN100445380C/zh not_active Expired - Fee Related
- 2000-12-12 AT AT07015976T patent/ATE455851T1/de not_active IP Right Cessation
- 2000-12-12 KR KR1020027007557A patent/KR100829646B1/ko not_active IP Right Cessation
- 2000-12-12 WO PCT/CA2000/001467 patent/WO2001044465A2/en active IP Right Grant
- 2000-12-12 JP JP2001545542A patent/JP4772245B2/ja not_active Expired - Fee Related
- 2000-12-12 DK DK00981117T patent/DK1238070T3/da active
- 2000-12-12 CZ CZ20022372A patent/CZ20022372A3/cs unknown
- 2000-12-12 HU HU0300627A patent/HUP0300627A3/hu unknown
- 2000-12-12 ES ES00981117T patent/ES2288883T3/es not_active Expired - Lifetime
- 2000-12-12 EP EP00981117A patent/EP1238070B1/en not_active Expired - Lifetime
- 2000-12-12 IL IL15019600A patent/IL150196A0/xx unknown
- 2000-12-12 MX MXPA02005842A patent/MXPA02005842A/es active IP Right Grant
- 2000-12-12 CA CA002393808A patent/CA2393808A1/en not_active Abandoned
- 2000-12-12 AT AT00981117T patent/ATE370231T1/de active
- 2000-12-12 DE DE60036019T patent/DE60036019T2/de not_active Expired - Lifetime
- 2000-12-12 PT PT00981117T patent/PT1238070E/pt unknown
- 2000-12-12 AU AU18479/01A patent/AU785212B2/en not_active Ceased
- 2000-12-12 US US09/735,363 patent/US7157436B2/en not_active Expired - Fee Related
- 2000-12-12 DE DE60043759T patent/DE60043759D1/de not_active Expired - Lifetime
- 2000-12-12 EP EP07015976A patent/EP1867718B1/en not_active Expired - Lifetime
- 2000-12-12 DK DK07015976.9T patent/DK1867718T3/da active
- 2000-12-12 CN CN2008101740188A patent/CN101491536B/zh not_active Expired - Fee Related
- 2000-12-12 ES ES07015976T patent/ES2340807T3/es not_active Expired - Lifetime
-
2002
- 2002-06-12 IL IL150196A patent/IL150196A/en not_active IP Right Cessation
- 2002-06-13 NO NO20022820A patent/NO330508B1/no not_active IP Right Cessation
-
2006
- 2006-12-18 US US11/641,542 patent/US20070213291A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003517041A5 (ja) | ||
JP2002519061A5 (ja) | ||
NZ522326A (en) | Adenosine A2A receptor antagonists | |
HUP0900587A3 (en) | Stable salts of 3,3-diphenylpropylamines and preparation thereof | |
JP2002060340A5 (ja) | ||
JP2002535332A5 (ja) | ||
JP2002532222A5 (ja) | ||
RS50031B (sr) | Triciklični inhibitori poli(adp-riboza)polimeraza | |
ZA200404306B (en) | 3'-prodrugs of 2'-deoxy-beta-L-nucleosides. | |
HUP0300527A3 (en) | Pyrrolopyrimidinone derivatives, process of preparation and use | |
AU2001280597A1 (en) | Compositions for sustained release of analgesic agents, and methods of making and using the same | |
MXPA03000661A (es) | Catalizador metalico shell y un precursor del mismo, proceso para su preparacion y uso del catalizador. | |
JP2002510633A5 (ja) | ||
EP1074549A3 (en) | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | |
AU2002305236A8 (en) | Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent | |
ZA200106102B (en) | Use of growth hormone secretagogues for improvement of functional health status. | |
ZA200105293B (en) | Use of growth hormone secretagogues for treatment of physical performance decline. | |
GB2369617B (en) | Novel 4,5-dihydroisoxazolylalkyl-piperazine or-piperidine derivatives having selective biological activity at dopamine D3orD4 receptor,and preparation thereof | |
JP2002506864A5 (ja) | ||
JP2002540769A5 (ja) | ||
CA2353205A1 (en) | Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient | |
MXPA03004498A (es) | Uso de pirazolo (4,3-d)pirimidinas. | |
JP2003516751A5 (ja) | ||
AU2001290989A1 (en) | Treatment of inflammatory bowel disease by the administration of delta5-androstene-3beta-ol-7,17 dione and metabolizable precursors thereof | |
MXPA03004907A (es) | Uso de pirazolo (4,3-d) pirimidinas. |